Table 1.

Demographic data, diagnoses, critical sample measurements and serial growth hormone concentrations following glucagon administration are shown.

Male, n (%)	16 (55%)
Age, years	1.8 (0.7, 3.4)
Height Z-score	−2.3 (−3.3, −1)
Weight Z-score	−1.2 (−2.3, −1)
Duration of fast, hours	15 (9.8, 20)
Final Diagnosis:
Hyperinsulinism Ketotic Hypoglycemia Mitochondrial Disorder Growth Hormone Deficiency	9 (31%) 13 (45%) 1 (4%) 6 (21%)
Lab Tests at End of Fast
Glucose, mg/dL	45 (42, 51.5)
Cortisol, mcg/dL	16 (10.3, 20.5)
Betahydroxybutyrate, mmol/L	2.4 (1.5, 2.75)
GH measurements (ng/ml)
Baseline (n=29)	2.6 (1, 3.5)
30 minutes (n=16)	2.5 (1.6, 8.2)
60 minutes (n=18)	4.9 (2.4, 10.7)
90 minutes (n=27)	5.6 (4.2, 12.9)
120 minutes (n=27)	4.4 (2.5, 10.2)
150 minutes (n=21)	5.1 (2.2, 11)
180 minutes (n=7)	3.2 (1.2, 11.6)
210 minutes (n=3)	3.6 (2, 4.9)
Number of subjects who exceeded threshold on testing
GH > 5 ng/ml at Baseline	4 (14%)
GH > 5 ng/ml after Serial Measurements	25 (86%)
GH > 7 ng/ml at Baseline	3 (10%)
GH > 7 ng/ml after Serial Measurements	19 (66%)
GH > 10 ng/ml at Baseline	1 (3%)
GH > 10 ng/ml after Serial Measurements	15 (52%)

Note that n represents the number of datapoints available for GH measurement at each timepoint. All data are presented as median (IQR).